6NX1

STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND-3 AKA 1,1,1,3,3,3-HEXAFLUORO-2-{4-[1-(4- LUOROBENZENESULFONYL)CYCLOPENTYL]PHENYL}PROPAN-2-OL


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.240 
  • R-Value Work: 0.211 
  • R-Value Observed: 0.212 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active ROR gamma t Inverse Agonists.

Duan, J.J.Lu, Z.Jiang, B.Stachura, S.Weigelt, C.A.Sack, J.S.Khan, J.Ruzanov, M.Galella, M.A.Wu, D.R.Yarde, M.Shen, D.R.Shuster, D.J.Borowski, V.Xie, J.H.Zhang, L.Vanteru, S.Gupta, A.K.Mathur, A.Zhao, Q.Foster, W.Salter-Cid, L.M.Carter, P.H.Dhar, T.G.M.

(2019) ACS Med Chem Lett 10: 367-373

  • DOI: 10.1021/acsmedchemlett.9b00010
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • A new phenyl (3-phenylpyrrolidin-3-yl)sulfone series of RORγt inverse agonists was discovered utilizing the binding conformation of previously reported bicyclic sulfonamide 1 . Through a combination of structure-based design and structure-act ...

    A new phenyl (3-phenylpyrrolidin-3-yl)sulfone series of RORγt inverse agonists was discovered utilizing the binding conformation of previously reported bicyclic sulfonamide 1 . Through a combination of structure-based design and structure-activity relationship studies, a polar set of amides at N 1-position of the pyrrolidine ring and perfluoroisopropyl group at para -position of the 3-phenyl group were identified as critical structural elements to achieve high selectivity against PXR, LXRα, and LXRβ. Further optimization led to the discovery of (1 R ,4r)-4-(( R )-3-((4-fluorophenyl)sulfonyl)-3-(4-(perfluoropropan-2-yl)phenyl)pyrrolidine-1-carbonyl)cyclohexane-1-carboxylic acid ( 26 ), which displayed excellent selectivity, desirable liability and pharmacokinetic properties in vitro , and a good pharmacokinetic profile in mouse. Oral administration of 26 demonstrated dose-dependent inhibition of IL-17 production in a mouse IL-2/IL-23-induced pharmacodynamic model and biologic-like efficacy in an IL-23-induced mouse acanthosis model.


    Organizational Affiliation

    Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Nuclear receptor subfamily 1 group I member 2,Nuclear receptor coactivator 1 fusion
A, B
351Homo sapiensMutation(s): 0 
Gene Names: NR1I2PXR
EC: 2.3.1.48
Find proteins for Q15788 (Homo sapiens)
Go to UniProtKB:  Q15788
NIH Common Fund Data Resources
PHAROS  Q15788
Find proteins for O75469 (Homo sapiens)
Go to UniProtKB:  O75469
NIH Common Fund Data Resources
PHAROS  O75469
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
L7D
Query on L7D

Download CCD File 
A, B
1,1,1,3,3,3-hexafluoro-2-(4-{1-[(4-fluorophenyl)sulfonyl]cyclopentyl}phenyl)propan-2-ol
C20 H17 F7 O3 S
BANKSZZTXXTYRE-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.27 Å
  • R-Value Free: 0.240 
  • R-Value Work: 0.211 
  • R-Value Observed: 0.212 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 84.195α = 90
b = 89.612β = 90
c = 106.158γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
PDB_EXTRACTdata extraction
HKL-2000data reduction
SCALEPACKdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2019-02-07 
  • Released Date: 2020-02-12 
  • Deposition Author(s): Khan, J.A.

Revision History 

  • Version 1.0: 2020-02-12
    Type: Initial release
  • Version 1.1: 2020-04-22
    Changes: Database references